| [1] | Bansal M, Gupta A, Ding HF. MYCN and metabolic reprogramming in neuroblastoma[J]. Cancers, 2022, 14(17): 4113. doi: 10.3390/cancers14174113
 | 
																													
																						| [2] | London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group[J]. J Clin Oncol, 2005, 23(27): 6459-6465. doi: 10.1200/JCO.2005.05.571
																																					pmid: 16116153
 | 
																													
																						| [3] | 中国抗癌协会小儿肿瘤专业委员会. 中华医学会小儿外科学分会肿瘤外科学组. 儿童神经母细胞瘤诊疗专家共识[J]. 中华小儿外科杂志, 2015, 36(1): 3-7. | 
																													
																						| [4] | Irwin MS, Naranjo A, Zhang FF, et al. Revised neur-oblastoma risk classification system: a report from the Children's Oncology Group[J]. J Clin Oncol, 2021, 39(29): 3229-3241. doi: 10.1200/JCO.21.00278
 | 
																													
																						| [5] | Vo KT, Matthay KK, Neuhaus J, et al. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project[J]. J Clin Oncol, 2014, 32(28): 3169-3176. doi: 10.1200/JCO.2014.56.1621
																																					pmid: 25154816
 | 
																													
																						| [6] | Salim A, Raitio A, Pizer B, et al. Neuroblastoma: the association of anatomical tumour site, molecular biology and patient outcomes[J]. ANZ J Surg, 2021, 91(5): 1000-1004. doi: 10.1111/ans.16595
																																					pmid: 33506998
 | 
																													
																						| [7] | Jahangiri L. Metastasis in neuroblastoma and its link to autophagy[J]. Life (Basel), 2023, 13(3): 818. | 
																													
																						| [8] | Raitio A, Rice MJ, Mullassery D, et al. Stage 4S neuroblastoma: what are the outcomes? a systematic review of published studies[J]. Eur J Pediatr Surg, 2021, 31(5): 385-389. doi: 10.1055/s-0040-1716836
 | 
																													
																						| [9] | Braoudaki M, Hatziagapiou K, Zaravinos A, et al. MYCN in neuroblastoma: "Old Wine into New Wineskins"[J]. Diseases, 2021, 9(4): 78. doi: 10.3390/diseases9040078
 | 
																													
																						| [10] | Ma Y, Zheng J, Feng J, et al. Neuroblastomas in eastern China: a retrospective series study of 275 cases in a regional center[J]. Peer J, 2018, 6: e5665. doi: 10.7717/peerj.5665
 | 
																													
																						| [11] | Campbell K, Gastier-Foster JM, Mann M, et al. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group[J]. Cancer, 2017, 123(21): 4224-4235. doi: 10.1002/cncr.30873
																																					pmid: 28696504
 | 
																													
																						| [12] | Ohira M, Nakamura Y, Takimoto T, et al. Retrospective analysis of INRG clinical and genomic factors for 605 neuroblastomas in Japan: A report from the Japan Children's Cancer Group Neuroblastoma Committee (JCCG-JNBSG)[J]. Biomolecules, 2021, 12(1): 18. doi: 10.3390/biom12010018
 | 
																													
																						| [13] | Su Y, Qin H, Chen C, Wang S, et al. Treatment and outcomes of 1041 pediatric patients with neuroblastoma who received multidisciplinary care in China[J]. Pediatr Investig, 2020, 4(3): 157-167. doi: 10.1002/ped4.v4.3
 | 
																													
																						| [14] | Zhang S, Zhang W, Jin M, et al. Biological features and clinical outcome in infant neuroblastoma: a multicenter experience in Beijing[J]. Eur J Pediatr, 2021, 180(7): 2055-2063. doi: 10.1007/s00431-021-03989-1
																																					pmid: 33580827
 | 
																													
																						| [15] | 贺思豆, 张诗晗, 岳志霞, 等. 伴MYCN扩增的婴儿神经母细胞瘤临床特征及预后分析[J]. 中国小儿血液与肿瘤杂志, 2022, 27(5): 5. | 
																													
																						| [16] | Ferraro S, Braga F, Luksch R, et al. Measurement of serum neuron-specific enolase in neuroblastoma: is there a clinical role?[J]. Clin Chem, 2020, 66(5): 667-675. doi: 10.1093/clinchem/hvaa073
																																					pmid: 32353141
 | 
																													
																						| [17] | Zhu FY, Yan J, Cao YN, Jin Y, et al. Early decline of neuron-specific enolase during neuroblastoma chemotherapy is a predictive factor of clinical outcome[J]. Pediatr Hematol Oncol, 2021, 38(6): 543-554. doi: 10.1080/08880018.2021.1894277
 | 
																													
																						| [18] | Sun Q, Chen Y, Jin Q, Yuan X, et al. A nomogram for predicting recurrence-free survival of intermediate and high-risk neuroblastoma[J]. Eur J Pediatr, 2022, 181(12): 4135-4147. doi: 10.1007/s00431-022-04617-2
 | 
																													
																						| [19] | 孙晓非, 甄子俊, 王娟, 等. 483例神经母细胞瘤基于危险因素分层治疗结果分析[J]. 中华小儿外科杂志, 2022, 43(3): 8. | 
																													
																						| [20] | Wang H, Wang X, Xu L, Zhang J, et al. Age related gene DST represents an independent prognostic factor for MYCN non-amplified neuroblastoma[J]. BMC Pediatr, 2021, 21(1): 272. doi: 10.1186/s12887-021-02753-6
																																					pmid: 34116676
 | 
																													
																						| [21] | Rubie H, De Bernardi B, Gerrard M, et al. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1[J]. J Clin Oncol, 2011, 29(4): 449-455. doi: 10.1200/JCO.2010.29.5196
																																					pmid: 21172879
 | 
																													
																						| [22] | 孙艳丽, 张锦华. 低剂量诱导分化治疗婴儿神经母细胞瘤的临床分析[J]. 国际儿科学杂志, 2019, 46(4): 308-310. | 
																													
																						| [23] | Nuchtern JG, London WB, Barnewolt CE, et al. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study[J]. Ann Surg, 2012, 256(4): 573-580. pmid: 22964741
 |